Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.43 per share and revenue of $1.1574 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals Trading Up 0.9%

NASDAQ:ALNY opened at $322.98 on Wednesday. The stock has a market cap of $42.67 billion, a price-to-earnings ratio of 1,345.75 and a beta of 0.35. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55. The business has a fifty day moving average of $384.02 and a 200-day moving average of $425.64.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ALNY. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price for the company. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Leerink Partners lowered their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president owned 22,511 shares in the company, valued at approximately $8,168,566.57. The trade was a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This trade represents a 9.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,305 shares of company stock valued at $16,972,485 in the last ninety days. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Orbis Allan Gray Ltd lifted its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $369,943,000. AQR Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after acquiring an additional 555,759 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Alnylam Pharmaceuticals by 73.6% in the 3rd quarter. Two Sigma Investments LP now owns 595,926 shares of the biopharmaceutical company’s stock valued at $271,742,000 after acquiring an additional 252,621 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Alnylam Pharmaceuticals by 113.1% in the 3rd quarter. Marshall Wace LLP now owns 508,371 shares of the biopharmaceutical company’s stock worth $231,817,000 after purchasing an additional 269,798 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.